Current AGITG trials in activation phase are:
Protocol Title: A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer
Study Chair: Dr Matthew Burge
Associate Oncology Program Manager: Cheryl Friend
Trial Coordinator: T.B.C.
Contact Email: firstname.lastname@example.org
Detailed information will be available shortly on: Australian and New Zealand Clinical Trials Registry
Trial Newsletter: None to date
- AGITG Innovation Fund ($100,000)
- Alan Bishop Fund ($20,000)
Design: A prospective randomised phase 2 study to assess the activity of panitumumab alone versus panitumumab plus 5FU as first line treatment for RAS wild type elderly patients with metastatic colorectal cancer
Key question: To evaluate the progression free survival and patient acceptability of both panitumumab alone and when given with 5FU as first line treatment in RAS wild type metastatic colorectal cancer.